-
1 Comment
Biotest Aktiengesellschaft is currently in a long term uptrend where the price is trading 15.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Biotest Aktiengesellschaft's total revenue rose by 14.8% to $143M since the same quarter in the previous year.
Its net income has increased by 122.2% to $400K since the same quarter in the previous year.
Finally, its free cash flow fell by 195.2% to $-6M since the same quarter in the previous year.
Based on the above factors, Biotest Aktiengesellschaft gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | DE0005227235 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Dividend Yield | 0.1% |
|---|---|
| Market Cap | 1B |
| Beta | 0.15 |
| PE Ratio | 45.15 |
| Target Price | 22.1 |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIO3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
